

AMENDMENTS TO THE CLAIMS

Claims 1-84 (Canceled)

Claim 85 (Currently Amended): A method of preparing an immunogenic composition, comprising the steps of:

- (a) providing an autologous target tumor or pathogen infected cell;
- (b) treating the tumor or pathogen infected cell with ~~a cytokine~~ IFN- γ and/or TNF- α to increase concentration of a primary T cell activation molecule or a costimulatory T cell activation molecule in the target tumor or pathogen infected cell;
- (c) providing a bispecific monoclonal antibody including one or more binding sites for one or more costimulatory molecules on a surface of one or more T cells of a patient mammal;
- (d) attaching the bispecific monoclonal antibody to the target tumor or pathogen infected cell; and
- (e) collecting a pharmaceutically effective amount of the target tumor or pathogen infected cell with the attached bispecific monoclonal antibody.

Claims 86-90 (Canceled)

Claim 91 (Previously submitted): The method of claim 85, wherein an autologous target tumor cell is provided.

Claim 92 (Previously submitted): The method of claim 91, wherein the tumor cell is selected from the group consisting of a hepatocellular carcinoma cell, a lymphoma cell, a colon carcinoma cell and a gastric cancer cell.

Claim 93 (Canceled).

Claim 94 (Previously submitted): The method of claim 85, wherein the T cell is selected from the group consisting of a CD3+, a CD8+ and a CD25+ T cell.

Claim 95 (Previously submitted): The method of claim 85, wherein the costimulatory T cell activation molecule is CD28 or 4-1BB molecule.

Claim 96 (Currently Amended): The method of claim 85, wherein the bispecific monoclonal antibody is a ~~CD28:gp115 or~~ CD28:gp55 bispecific monoclonal antibody.

Claim 97 (Previously submitted): The method of claim 85, wherein the bispecific monoclonal antibody includes two or more binding sites for two or more costimulatory molecules on a surface of one or more T cells of a patient mammal.

Claim 98 (Currently Amended): The method of claim 85, wherein the ~~patient mammal~~ autologous target tumor or pathogen infected cell is a human cell.

Claim 99 (Previously submitted): The method of claim 85, further comprising removing the bispecific monoclonal antibody not attached to the target tumor or pathogen infected cell before step (e).

Claim 100 (Currently Amended): A method of preparing an immunogenic composition, comprising the steps of:

- (a) providing an autologous target tumor cell;
- (b) treating the tumor cell with IFN- γ and/or TNF- α to increase concentration of CD28 in the target tumor cell;
- (c) providing a ~~CD28:gp115 or~~ CD28:gp55 bispecific monoclonal antibody;
- (d) attaching the ~~CD28:gp115 or~~ CD28:gp55 bispecific monoclonal antibody to the target tumor cell; and
- (e) collecting a pharmaceutically effective amount of the target tumor cell with the attached ~~CD28:gp115 or~~ CD28:gp55 bispecific monoclonal antibody.